SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 57.05-0.6%Dec 9 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (6589)6/20/2002 12:38:45 PM
From: Biomaven  Read Replies (4) of 52153
 
I am not that enthusiastic on Pralnacasan

The numbers looked very solid to me once you remove the patients on MTX for a short time. In terms of overall efficacy, remember we are looking only at 12 week data. Mild to moderate is all you have left nowadays, as any severe patients will undoubtedly have already received Remicade or Enbrel.

1.2g is indeed a big dose, but still practicable. There was a good dose/response relationship - this showed up mostly in the steroid-sparing extension of the trial.

They didn't discuss PK at all.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News